A phase 2 clinical trial of a new coronavirus vaccine in China has yielded good results

LONDON, July 20 (Xinhua Zhang Jiawei Yu Jiaxin) The Chinese research team said in a paper published in the British medical journal The Lancet on the 20th that they have conducted Phase 2 clinical trials of a new coronavirus vaccine, which has been shown to be safe and can induce the body to produce an immune response.
clinical trial was
by researchers such as Chen Wei
of the Institute of Bioengineering of the Military Medical Research Institute of China and Professor Zhu Fengcai of the Jiangsu Provincial Center for Disease Control and Prevention. The team has previously completed Phase 1 clinical trials of the vaccine, and the results have been published.
tests evaluated a new coronavirus vaccine recombined by adenovirus vectors. According to the paper, more than 500 volunteers, including people over 55 years of age, participated in the Phase 2 clinical trial in China, a larger range of participants than in phase 1 clinical trials. The purpose of the trial was to assess whether the vaccine induced an immune response and whether it was safe enough, and the results showed that the vaccine produced good results in both areas.
Jufengcai Zhu said in a Lancet press release that Phase 2 clinical trials provide further evidence for the safety and immunogenicity of vaccines in a wider population than Phase 1 clinical trials, which is an "important step" in evaluating candidate vaccines, and that the team is currently conducting Phase 3 clinical trials.
researchers also noted that the volunteers involved in the trial were not exposed to the new coronavirus after vaccination, so it is not possible to judge whether the vaccine is effective in protecting people from the new coronavirus, and that phase 3 clinical trials are needed for further validation.
the Lancet, there are currently about 250 candidates for the new coronavirus vaccine in development worldwide, at least 17 of which are in clinical trials.